Physician profile
Farhan Mohammad
NPI 1184902512
$4,780.90
in general payments reported to CMS, 2019-2025
53 companies · $1,001 in 2025
The $1,001 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $514 · 2020: $156 · 2021: $170 · 2022: $335 · 2023: $1,327 · 2024: $1,277 · 2025: $1,001.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,562 · Education: $43.61.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,561.79 |
| Education | $43.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $664.23 | 2019-2025 | Imfinzi, Lynparza, Calquence |
| Pfizer INC. | $458.26 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $399.88 | 2019-2025 | Opdivo |
| Janssen Biotech, INC. | $296.16 | 2020-2025 | Tecvayli, Darzalex, Talvey |
| Novartis Pharmaceuticals Corporation | $253.42 | 2019-2025 | |
| Incyte Corporation | $236.42 | 2022-2025 | Jakafi, Monjuvi, Niktimvo |
| Merck Sharp & Dohme LLC | $171.09 | 2019-2025 | Keytruda, Welireg, Keytruda Qlex |
| Gilead Sciences, INC. | $158.14 | 2021-2025 | Trodelvy |
| Genzyme Corporation | $157.89 | 2020-2024 | |
| Celgene Corporation | $143.82 | 2019-2025 | Reblozyl, Pomalyst |
| Medtronic, INC. | $131.35 | 2021-2024 | Osteocool Rf Ablation System, Kyphon Express II Kyphopak Tray |
| Daiichi Sankyo INC. | $124.99 | 2023-2025 | Injectafer, Vanflyta, Enhertu |
| Array Biopharma INC | $112.61 | 2023-2025 | Mektovi, Braftovi, Xalkori |
| Myriad Genetic Laboratories, INC. | $96.89 | 2022-2023 | Precisetumor |
| Astellas Pharma US INC | $96.89 | 2020-2025 | Padcev, Vyloy |
Show all 53 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Farhan Mohammad listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.